MATTEK joins the Industry Alliance for Microphysiological Systems
Göttingen, Germany | Brussels, Belgium
- MATTEK joins Industry Alliance for Microphysiological Systems (IAMPS) as its tenth member.
- IAMPS is the world’s first microphysiological systems (MPS) association and the industry voice for the sector in the EU.
- MATTEK brings its human cell-based 3D tissue models to the alliance’s push for regulatory adoption of new approach methodologies.
MATTEK, a subsidiary of the life science group Sartorius and a leading developer and manufacturer of human cell-based microtissues and 3D models, has joined the Industry Alliance for Microphysiological Systems as its tenth member, expanding the world’s first microphysiological systems association and reinforcing the company’s commitment to qualifying and deploying advanced in vitro models.
IAMPS is the industry voice of MPS providers in the European Union (EU), bringing together companies developing organoids, organs-on-chips, and related human biology-based technologies. It supports the development, adoption, and regulatory acceptance of these advanced new approach methodologies (NAMs).
“We are delighted to welcome MATTEK to IAMPS,” said Thibault Honegger, President of IAMPS. “As a pioneer and leader of the tissue engineering and 3D-reconstructed human tissue models industry, they will bring invaluable experience to the association. They will add their strength to our efforts to accelerate the regulatory adoption of MPS and foster an effective European industrial strategy for the sector.”
“Too many promising drug candidates fail in clinical development because traditional preclinical models don’t always predict human outcomes,” said Gwen Fewell, Head of Advanced Cell Models at Sartorius. MATTEK develops human tissue models that help researchers generate more human-relevant data earlier in development, enabling researchers to make better-informed decisions. “By joining IAMPS, we are strengthening our commitment to advancing regulatory acceptance of microphysiological systems and new approach methodologies working alongside industry leaders, regulators and policymakers across Europe.”
“MATTEK develops microphysiological models and methods that form the building blocks of integrated NAMs targeting multi-organ and systemic endpoints,” said Alex Armento, Head of MATTEK. “Joining IAMPS is a natural fit because we share the same goal of advancing NAMs in Europe through standardized, validated methods and constructive dialogue with regulators.”
The move comes at a critical time for MPS in Europe. In December 2025, the European Commission published a draft EU Biotech Act1 listing the integration of NAMs2 in preclinical development and regulatory testing as “health biotechnology strategic projects.” In June, it published a roadmap towards phasing out animal testing for chemical safety assessments3, which aims to gradually replace animal tests with “non-animal approaches” across many regulatory areas, while recognizing that “both reduction and refinement remain important stepping stones along this path,” in line with the 3R principle.
IAMPS works with the European Commission and its agencies to accelerate the regulatory recognition of MPS in specific preclinical contexts of use, and advocates for targeted funding to deploy MPS models at scale in the EU. Mattek joins founding members AlveoliX, BiomimX, Dynamic42, chiron, InSphero, MIMETAS, NETRI, React4life, and TissUse.
More information about MATTEK:
MATTEK is a leading developer and manufacturer of human cell-based microtissues and 3D models and joined Sartorius in 2025.
2 Defined as “innovative methods that do not involve live animals, such as in vitro (cell or tissue-based), in chemico (chemical-based), or in-silico (computer-based) approaches, as well as combinations of these”
